Nephros Historical Balance Sheet

NEPH Stock

USD 1.55 0.04 2.65%

Trend analysis of Nephros balance sheet accounts such as Accounts Payable of 711 K provides information on Nephros' total assets, liabilities, and equity, which is the actual value of Nephros to its prevalent stockholders. By breaking down trends over time using Nephros balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Nephros latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nephros is a good buy for the upcoming year.

Nephros Inventory

1.44 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.

About Nephros Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Nephros at a specified time, usually calculated after every quarter, six months, or one year. Nephros Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Nephros and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Nephros currently owns. An asset can also be divided into two categories, current and non-current.

Nephros Balance Sheet Chart

As of now, Nephros' Property Plant Equipment is increasing as compared to previous years. The Nephros' current Total Stockholder Equity is estimated to increase to about 8.8 M, while Total Assets are projected to decrease to under 7.5 M.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable Other Assets Long Term Debt

Add Fundamental

Total Assets

Total assets refers to the total amount of Nephros assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Nephros books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Nephros balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Nephros are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Nephros obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Nephros are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Long Term Debt

Long-term debt is a debt that Nephros has held for over one year. Long-term debt appears on Nephros balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Nephros balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most accounts from Nephros' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Nephros current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.As of now, Nephros' Property Plant Equipment is increasing as compared to previous years. The Nephros' current Total Stockholder Equity is estimated to increase to about 8.8 M, while Total Assets are projected to decrease to under 7.5 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	448K	268K	312K	456.2K
Total Assets	17.7M	11.0M	11.9M	7.5M

Other Current Liab Total Assets

Nephros balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Cash	Other Assets	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Preferred Stock Total Equity	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.21	-0.06	-0.24	0.98	-0.12	0.8	0.63	-0.07	0.4	-0.23	0.61	0.58	0.88	0.68	-0.58	-0.92	-0.61	0.89	-0.49	0.98	-0.23	-0.43	0.7	0.54	0.99
Other Current Liab	0.21		0.39	0.41	0.08	0.38	0.17	0.38	0.29	0.36	-0.23	0.2	0.18	0.3	0.23	-0.05	-0.18	-0.4	0.46	0.47	0.11	-0.24	-0.14	0.32	0.23	0.13
Total Current Liabilities	-0.06	0.39		0.53	-0.1	0.33	-0.3	-0.04	0.09	0.04	-0.27	-0.07	0.29	-0.11	-0.17	0.44	0.18	0.24	0.1	0.34	-0.12	-0.27	0.14	-0.18	-0.15	-0.1
Accounts Payable	-0.24	0.41	0.53		-0.31	0.03	-0.37	-0.02	0.09	-0.38	-0.29	-0.09	-0.23	-0.38	-0.21	-0.02	0.3	0.52	-0.07	0.32	-0.33	-0.29	0.18	-0.49	-0.2	-0.26
Cash	0.98	0.08	-0.1	-0.31		-0.1	0.74	0.58	-0.06	0.32	-0.18	0.51	0.58	0.84	0.62	-0.56	-0.94	-0.54	0.8	-0.53	0.99	-0.18	-0.37	0.63	0.49	0.99
Other Assets	-0.12	0.38	0.33	0.03	-0.1		-0.47	0.01	0.45	0.1	-0.26	-0.48	0.0	-0.19	-0.29	0.45	0.01	0.16	-0.07	0.66	-0.12	-0.27	0.39	-0.1	-0.3	-0.15
Common Stock Shares Outstanding	0.8	0.17	-0.3	-0.37	0.74	-0.47		0.44	-0.16	0.44	-0.07	0.81	0.48	0.86	0.85	-0.74	-0.68	-0.82	0.74	-0.62	0.78	-0.07	-0.46	0.75	0.79	0.78
Other Current Assets	0.63	0.38	-0.04	-0.02	0.58	0.01	0.44		-0.12	0.21	-0.29	0.4	-0.09	0.63	0.37	-0.43	-0.73	-0.39	0.6	0.0	0.58	-0.3	-0.26	0.44	0.28	0.61
Total Liab	-0.07	0.29	0.09	0.09	-0.06	0.45	-0.16	-0.12		0.19	0.02	-0.12	0.05	-0.31	-0.11	0.13	0.03	-0.08	0.1	0.4	-0.06	0.02	0.55	0.04	-0.09	-0.12
Preferred Stock Total Equity	0.4	0.36	0.04	-0.38	0.32	0.1	0.44	0.21	0.19		0.19	0.26	0.41	0.51	0.3	0.02	-0.27	-0.76	0.6	0.1	0.3	0.19	-0.35	0.84	0.32	0.29
Common Stock	-0.23	-0.23	-0.27	-0.29	-0.18	-0.26	-0.07	-0.29	0.02	0.19		-0.48	-0.05	-0.14	-0.49	0.26	0.24	-0.18	-0.23	0.01	-0.19	1.0	-0.16	0.2	-0.44	-0.24
Property Plant Equipment	0.61	0.2	-0.07	-0.09	0.51	-0.48	0.81	0.4	-0.12	0.26	-0.48		0.38	0.65	0.91	-0.64	-0.48	-0.56	0.64	-0.51	0.56	-0.48	-0.31	0.45	0.87	0.59
Short Long Term Debt Total	0.58	0.18	0.29	-0.23	0.58	0.0	0.48	-0.09	0.05	0.41	-0.05	0.38		0.56	0.49	-0.04	-0.38	-0.47	0.55	-0.33	0.59	-0.06	-0.31	0.47	0.43	0.56
Total Stockholder Equity	0.88	0.3	-0.11	-0.38	0.84	-0.19	0.86	0.63	-0.31	0.51	-0.14	0.65	0.56		0.76	-0.51	-0.82	-0.77	0.78	-0.45	0.86	-0.15	-0.62	0.77	0.68	0.87
Property Plant And Equipment Net	0.68	0.23	-0.17	-0.21	0.62	-0.29	0.85	0.37	-0.11	0.3	-0.49	0.91	0.49	0.76		-0.71	-0.6	-0.6	0.64	-0.51	0.67	-0.49	-0.28	0.47	0.98	0.68
Current Deferred Revenue	-0.58	-0.05	0.44	-0.02	-0.56	0.45	-0.74	-0.43	0.13	0.02	0.26	-0.64	-0.04	-0.51	-0.71		0.54	0.34	-0.51	0.51	-0.58	0.26	0.09	-0.29	-0.65	-0.6
Net Debt	-0.92	-0.18	0.18	0.3	-0.94	0.01	-0.68	-0.73	0.03	-0.27	0.24	-0.48	-0.38	-0.82	-0.6	0.54		0.52	-0.72	0.4	-0.95	0.24	0.4	-0.58	-0.48	-0.94
Retained Earnings	-0.61	-0.4	0.24	0.52	-0.54	0.16	-0.82	-0.39	-0.08	-0.76	-0.18	-0.56	-0.47	-0.77	-0.6	0.34	0.52		-0.69	0.2	-0.57	-0.17	0.46	-0.93	-0.57	-0.55
Non Current Assets Total	0.89	0.46	0.1	-0.07	0.8	-0.07	0.74	0.6	0.1	0.6	-0.23	0.64	0.55	0.78	0.64	-0.51	-0.72	-0.69		-0.21	0.78	-0.23	-0.33	0.78	0.52	0.82
Non Currrent Assets Other	-0.49	0.47	0.34	0.32	-0.53	0.66	-0.62	0.0	0.4	0.1	0.01	-0.51	-0.33	-0.45	-0.51	0.51	0.4	0.2	-0.21		-0.55	0.0	0.4	-0.19	-0.45	-0.56
Cash And Short Term Investments	0.98	0.11	-0.12	-0.33	0.99	-0.12	0.78	0.58	-0.06	0.3	-0.19	0.56	0.59	0.86	0.67	-0.58	-0.95	-0.57	0.78	-0.55		-0.19	-0.38	0.62	0.55	0.99
Common Stock Total Equity	-0.23	-0.24	-0.27	-0.29	-0.18	-0.27	-0.07	-0.3	0.02	0.19	1.0	-0.48	-0.06	-0.15	-0.49	0.26	0.24	-0.17	-0.23	0.0	-0.19		-0.16	0.2	-0.44	-0.24
Non Current Liabilities Total	-0.43	-0.14	0.14	0.18	-0.37	0.39	-0.46	-0.26	0.55	-0.35	-0.16	-0.31	-0.31	-0.62	-0.28	0.09	0.4	0.46	-0.33	0.4	-0.38	-0.16		-0.51	-0.24	-0.43
Other Stockholder Equity	0.7	0.32	-0.18	-0.49	0.63	-0.1	0.75	0.44	0.04	0.84	0.2	0.45	0.47	0.77	0.47	-0.29	-0.58	-0.93	0.78	-0.19	0.62	0.2	-0.51		0.4	0.63
Property Plant And Equipment Gross	0.54	0.23	-0.15	-0.2	0.49	-0.3	0.79	0.28	-0.09	0.32	-0.44	0.87	0.43	0.68	0.98	-0.65	-0.48	-0.57	0.52	-0.45	0.55	-0.44	-0.24	0.4		0.54
Total Current Assets	0.99	0.13	-0.1	-0.26	0.99	-0.15	0.78	0.61	-0.12	0.29	-0.24	0.59	0.56	0.87	0.68	-0.6	-0.94	-0.55	0.82	-0.56	0.99	-0.24	-0.43	0.63	0.54

Click cells to compare fundamentals

Nephros Account Relationship Matchups

Nephros balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	11.6M	18.5M	17.7M	11.0M	11.9M	7.5M
Other Current Liab	300K	341K	448K	268K	312K	456.2K
Total Current Liabilities	2.4M	1.3M	2.4M	1.4M	2.1M	1.6M
Accounts Payable	959K	423K	1.3M	740K	873K	711.0K
Cash	4.2M	8.2M	7.0M	3.6M	4.3M	2.7M
Other Assets	32K	1.8M	89K	54K	62.1K	59.0K
Common Stock Shares Outstanding	7.5M	9.1M	10.0M	10.3M	10.4M	10.9M
Other Current Assets	61K	237K	558K	188K	132K	161.6K
Total Liab	3.9M	2.9M	2.9M	2.1M	3.5M	2.9M
Property Plant Equipment	1.2M	295K	1.1M	1.1M	1.3M	1.3M
Short Long Term Debt Total	2.5M	2.2M	1.1M	1.1M	1.8M	1.7M
Total Stockholder Equity	4.7M	12.5M	11.7M	5.6M	8.4M	8.8M
Property Plant And Equipment Net	1.2M	1.3M	1.1M	1.1M	2.0M	2.1M
Net Debt	(1.6M)	(6.1M)	(5.9M)	(2.5M)	(2.5M)	(2.3M)
Retained Earnings	(127.3M)	(131.9M)	(135.7M)	(142.8M)	(144.4M)	(151.6M)
Non Current Assets Total	3.3M	3.4M	4.0M	2.7M	3.5M	1.8M
Non Currrent Assets Other	18K	32K	89K	54K	86K	81.7K
Cash And Short Term Investments	4.2M	8.2M	7.0M	3.6M	4.3M	3.7M
Liabilities And Stockholders Equity	11.6M	18.5M	17.7M	11.0M	11.9M	7.8M
Non Current Liabilities Total	1.5M	1.6M	511K	706K	1.4M	2.0M
Other Stockholder Equity	131.9M	144.3M	147.3M	148.4M	152.8M	109.1M
Property Plant And Equipment Gross	1.2M	1.3M	1.1M	1.1M	2.9M	3.1M
Total Current Assets	8.3M	15.2M	13.6M	8.3M	8.4M	6.1M
Short Term Debt	1.2M	1.0M	561K	387K	892K	744.8K
Inventory	2.6M	5.3M	4.8M	3.2M	2.5M	1.4M
Net Receivables	1.0M	1.4M	1.6M	1.3M	1.5M	806.7K
Long Term Debt	623K	846K	95K	1K	900.0	855.0
Intangible Assets	1.4M	1.2M	2.1M	825K	652K	1.1M
Net Tangible Assets	2.6M	10.6M	8.9M	4.0M	4.6M	2.7M
Capital Surpluse	122.9M	127.8M	131.9M	144.3M	165.9M	134.3M

Currently Active Assets on Macroaxis

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft
HBI	Hanesbrands
STLD	Steel Dynamics

When determining whether Nephros offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nephros' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nephros Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nephros Stock:

How To Invest In Nephros

Details

Is Nephros Stock a good investment?

Details

What is Nephros' Net Worth?

Details

Largest Medical Instruments & Supplies Companies

View

Largest Consumer Discretionary Companies

View

For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Is Household Appliances space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.09)

Revenue Per Share

1.313

Quarterly Revenue Growth

(0.08)

Return On Assets

(0.08)

Return On Equity

(0.16)

The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nephros Historical Balance Sheet

Nephros Inventory

1.44 Million

About Nephros Balance Sheet Analysis

Nephros Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Long Term Debt

Nephros balance sheet Correlations

Nephros Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nephros balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock Total Equity	+ 1.0	Common Stock
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash	+ 0.98	Total Assets

Cash And Short Term Investments	- 0.95	Net Debt
Total Current Assets	- 0.94	Net Debt
Net Debt	- 0.94	Cash
Other Stockholder Equity	- 0.93	Retained Earnings
Net Debt	- 0.92	Total Assets
Net Debt	- 0.82	Total Stockholder Equity